Bimiralisib, Topical PI3K/mTOR Inhibitor Shows Up To 92% Clearance Rate And Superior Tolerability In Proof-Of-Concept Actinic Keratosis Study
Torqur AG Announced Full Phase 2 Results at EADV Congress 2025 BASEL, Switzerland — Torqur AG, subsidiary of Swiss Rockets incubator and a clinical-stage company advancing targeted therapies in oncodermatology and oncology, announced the results of the full P
(Financial Post, 2025-10-06T09:50:11Z)